Bakgrunn: Vekttap og underernaering er en vanlig sekundaerdiagnose for kreftpasienter i palliativ fase. Det fører ofte til at pasienter blir behandlet med parenteral ernaering. Når kreftpasienter går inn i livets siste fase, viser forskning uklar klinisk nytte av behandling med parenteral ernaering. Behandling og avslutning av behandlingen kan dernest føre til utfordringer for helsepersonell, pasienter og pårørende. Få kvalitative studier er gjort om helsepersonells erfaringer med parenteral ernaering i livets sluttfase. Hensikt: Hensikten med denne studien var å beskrive hvilke utfordringer helsepersonell på sykehus opplever knyttet til behandling med parenteral ernaering til kreftpasienter i livets sluttfase. Metode: Kvalitativ studie med individuelle intervjuer av seks sykepleiere og to onkologer som jobber med kreftpasienter ved to sykehus på Østlandet. Vi brukte systematisk tekstkondensering for å analysere dataene. Resultat: Analysen avdekket ett overordnet tema: Beslutninger om å avslutte parenteral ernaering i livets sluttfase krever rik erfaringskunnskap og samhandling mellom leger og sykepleiere. To hovedkategorier fremkom: 1) dialog, re eksjon og informasjon om liv og død til pasienter og pårørende 2) vurderingsperspektiv og kjennskap til pasienten
Background: Weight loss and undernourishment are common secondary diagnoses for cancer patients in the palliative phase. This often means that patients are treated with parenteral nutrition. Research shows that there is no clear benefit from treatment with parenteral nutrition when cancer patients approach the end of life. Whether to continue or stop the treatment can therefore represent a challenge for healthcare personnel, patients and their relatives. Few qualitative studies have investigated how healthcare personnel experience their work with parenteral nutrition at the end of life.Objective: The study's objective was to describe the challenges that healthcare personnel in hospitals experience in connection with administering parenteral nutrition to cancer patients at the end of life.Method: Qualitative study involving individual interviews with six registered nurses and two oncologists who work with cancer patients at two hospitals in eastern Norway. We made use of systematic text condensation to analyse the data. Results:The analysis revealed one overarching theme: making decisions about whether to stop parenteral nutrition at the end of life requires extensive experiencebased knowledge and interaction between doctors and registered nurses. Two main categories emerged: 1 dialogue, reflection and providing information about life and death to patients and their relatives 2 assessment perspectives and knowing the patient. Conclusion:The participants described the importance of communicating information about end-of-life parenteral nutrition at an early stage of the disease. The study suggests a need for clear routines and guidelines for parenteral nutrition, although the participants describe experience-based knowledge and interdisciplinary collaboration as the most important factors in assessing the patient's condition.A Norwegian study showed that 66 per cent of cancer patients on a palliative care ward, suffered from undernourishment 1 . Food and drink are essential parts of life, and cancer patients who are nearing the end of life, will often have a waning interest in food and drink 2 .When patients are unable to absorb sufficient nutrition orally or enterally, parenteral nutrition can be appropriate 3 . Parenteral nutrition is a medical treatment that involves administering intravenous nutrition straight into the vein 4 .Indications to start parenteral nutrition include expected shortening of life due to undernourishment, expected improvement to the quality of life, or that this is in accordance with the wishes of patients and their relatives 3 5 . Definition of the end of lifeIn a clinical context, healthcare personnel often define the end of life in different ways. It is far from easy to pinpoint the start of this phase. The Norwegian Association for Palliative Care and the Norwegian Association for Palliative Medicine define the end of life in this way: When the remaining life expectancy is likely, on balance, to be severely limited, often a matter of weeks or days. 6
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.